A Network-Based Model of Oncogenic Collaboration for Prediction of Drug Sensitivity

Ted G Laderas1, Laura M Heiser2, Kemal Sönmez2

  • 1OHSU Knight Cancer Institute, Oregon Health & Science University, PortlandOR, USA; Department of Medical Informatics and Clinical Epidemiology, Oregon Health & Science University, PortlandOR, USA.

Frontiers in Genetics
|January 19, 2016
PubMed

Insights

We introduce "surrogate oncogenes," mutated genes interacting with known oncogenes, to improve cancer treatment. This approach predicts drug sensitivity and patient survival, offering new avenues for precision medicine and drug development.

Area of Science:

  • Genomics
  • Cancer Biology
  • Computational Biology

Background:

  • Tumorigenesis involves multiple oncogenic mutations, complicating precision medicine.
  • Oncogenic collaboration, where multiple mutations drive cancer, poses treatment challenges.
  • Identifying therapeutically-actionable mutations from omic data is crucial for targeted therapies.

Purpose of the Study:

  • To propose and validate a novel genomic feature, "surrogate oncogenes," representing mutated subnetworks interacting with known oncogenes.
  • To assess the utility of surrogate oncogenes in predicting drug sensitivity and patient survival in breast cancer.
  • To explore the prevalence and potential application of surrogate oncogenes across multiple cancer types.

Main Methods:

  • Mapping mutations to protein-protein interaction networks.
  • Utilizing permutation-based methods to determine the statistical significance of surrogate oncogenes.
  • Employing Random Forest Classifiers to predict drug sensitivity and survival outcomes.
  • Analyzing data from breast cancer cell lines and The Cancer Genome Atlas (TCGA).

Main Results:

  • Identified significant surrogate oncogenes interacting with known oncogenes like BRCA1 and ESR1 in breast cancer cell lines.
  • Demonstrated that surrogate oncogenes predict drug sensitivity for 74 drugs with a mean error rate of 30.9%.
  • Showed surrogate oncogenes are predictive of patient survival and are prevalent across multiple cancer types.

Conclusions:

  • Surrogate oncogenes represent a novel genomic feature that captures oncogenic collaboration.
  • This framework enhances drug sensitivity prediction and survival analysis, offering a new direction for precision medicine.
  • Surrogate oncogenes have potential for guiding pan-cancer analyses and therapy assignment across diverse cancer types.

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
Protein Networks02:26

Protein Networks

An organism can have thousands of different proteins, and these proteins must cooperate to ensure the health of an organism. Proteins bind to other proteins and form complexes to carry out their functions. Many proteins interact with multiple other proteins creating a complex network of protein interactions.
These interactions can be represented through maps depicting protein-protein interaction networks, represented as nodes and edges. Nodes are circles that are representative of a protein,...
4.7K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K
Pharmacodynamic Models: Additive and Proportional Drug Effect Model01:09

Pharmacodynamic Models: Additive and Proportional Drug Effect Model

Drug response models describe how pharmacological agents interact with biological systems to produce measurable effects. Baseline responses are inherent physiological activities without a drug significantly influencing the observed pharmacological outcomes. Depending on the drug response model employed, these baseline responses may combine with the drug's effect in either an additive or proportional manner.Additive Drug Response ModelIn the additive model, the drug effect is independent of the...
61
Pharmacodynamic Models: Emax Drug–Concentration Effect Model01:18

Pharmacodynamic Models: Emax Drug–Concentration Effect Model

The Emax drug-concentration effect model is central to pharmacodynamics in drug discovery and development. This model is predicated on the receptor occupancy theory, which posits that the effect of a drug is directly related to the number of receptors occupied by the drug and the resultant complex formation.The model describes the reversible interaction between a drug (C) and a receptor (R) to form a drug-receptor complex (RC). The kinetics of this interaction are quantified by an equation that...
127